Date correction published: 16/12/2025
Original publication¹
A corrigendum has been made to this article, which was originally published on 11.11.25, in line with compliance requirements to include the European Summary of Product Characteristics (SmPC) of cabotgravir▼, rilpivirine▼, and dolutegravir/lamivudine.
Reference:
1. Gandhi M et al. Addressing Clinical Challenges in HIV with Evidence-Based Insights. Available at: https://www.emjreviews.com/microbiology-infectious-diseases/article/addressing-clinical-challenges-in-hiv-with-evidence-based-insights/. Last accessed: 5 December 2025.
